Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01192594 · ClinicalTrials.gov registry record · Phase 3
Milestones of Adjustment Post-Psychosis
A Phase 3 study, sponsored by Yale University.
- Terminated
- Registry status
- Phase 3
- Development phase
- 110
- Enrollment target
NCT01192594: Clinical Trial Phase 3 study, sponsored by Yale University.
NCT01192594 is a Phase 3 study that was terminated before completion, run by Yale University. The registered enrollment target is 110 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (86% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01192594, a Phase 3 study, was terminated before completion, sponsored by Yale University.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 110 participants
- Enrollment target
Study Summary
This nested design clinical outcome study of psychiatric case manager education on disease state, psychopharmacology of schizophrenia, relapse, motivational interviewing, and the process of psychological adjustment post-psychosis (Milestones of Adjustment Post-Psychosis Recovery Model-MAPP) will test the following hypotheses: 1. Medication non-adherence in patients with schizophrenia assigned to case managers who receive MAPP training will decrease from their pre-study rate and from the reported national average after one year enrollment compared to consumers not enrolled in the MAPP arm of the study. 2. Consumers in the MAPP intervention will have higher Quality of Life Enjoyment and Satisfaction Questionnaire (Q-Les-Q (53) scores than consumers not enrolled in the MAPP at quarterly measures. 3. Consumers enrolled in the MAPP intervention arm of the study will successfully complete the first two phases of the MAPP Recovery Model in one year. 4. Consumers in the MAPP intervention arm will have greater symptom reductions at quarterly data points compared to consumers not enrolled in the MAPP intervention arm.
Primary Outcome
Specific consumer medication adherence outcome data will be collected quarterly for both groups for two years targeting two specific analyses of change: pharmacy records of prescription refills one year before and quarterly after the educational intervention. These records will be obtained by informed consent from the consumer and respective pharmacies.
Interventions
- BEHAVIORAL Training in all modules including MAPP Recovery Model
- BEHAVIORAL Training in all modules except MAPP Recovery Model
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2009-11 |
| Est. Completion | 2013-01 |
| Phase | Phase 3 |
Why NCT01192594 stopped before completion
NCT01192594 is an interventional study that assigns participants to a tested intervention. The registered 110 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (86% lower).
The record links to 0 conditions, and to 2 interventions - of which Training in all modules including MAPP Recovery Model is the first listed.
NCT01192594 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01192594 about?
NCT01192594 is a clinical study titled "Milestones of Adjustment Post-Psychosis". This nested design clinical outcome study of psychiatric case manager education on disease state, psychopharmacology of schizophrenia, relapse, motivational interviewing, and the process of psychological adjustment post-psychosis (Milestones of Adjustment Post-Psychosis Recovery Model-MAPP) will tes...
What is the current status of trial NCT01192594?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 110 participants. The study started on 2009-11. Estimated completion is 2013-01.
What interventions are being tested in trial NCT01192594?
The interventions under investigation include: Training in all modules including MAPP Recovery Model (BEHAVIORAL), Training in all modules except MAPP Recovery Model (BEHAVIORAL).
Who is sponsoring clinical trial NCT01192594?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01192594's enrollment target sits among peer trials
110 1657th of 2000 higher than 337 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01530373 · 110 participants · Phase 2
Solifenacin Compared to Clonidine for Reducing Hot Flashes Among Breast Cancer Patients
- NCT02379377 · 110 participants · Phase 1
18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant
- NCT02411773 · 110 participants · Phase 1
Sympatholysis in Chronic Kidney Disease
- NCT03190941 · 110 participants · Phase 1
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia